基于聚电解质复合物的水凝插件用于阴道输送波萨可纳和益生菌
Sanjeevani Deshkar1, Purva Yeole1, Jayashri Mahore1
1Department of Pharmaceutics, Dr. D. Y. Patil Unitech Society's, Dr. D. Y. Patil Institute of Pharmaceutical Science & Research, Pune 411018, India.
Gels (Basel, Switzerland)
|November 24, 2023
概括
这项研究开发了新型的阴道水凝插件,使用奇托桑 - pectin多电解质复合物治疗复发性生殖道感染. 插件有效地输送了波萨科纳和Lactobacillus casei,减少了Candida albicans和恢复了阴道微生物群.
科学领域:
- 制药科学 制药科学
- 生物材料科学 生物材料科学
- 微生物学 微生物学
背景情况:
- 生殖系统感染 (RTIs) 影响全球40-50%的女性,通常以反复复发的混合感染形式呈现,这些感染对标准抗菌/抗真菌治疗有抗性.
- 目前的治疗需要结合口服和局部疗法来缓解症状,强调需要改进局部药物输送系统.
- 开发先进的阴道输送系统对于提高治疗疗效和患者遵守常见RTIs至关重要.
研究的目的:
- 优化和配制桑/离子的多电解质复合物 (PEC) 用于阴道水凝插件.
- 将波萨可纳和益生菌*Lactobacillus casei*纳入这些水凝插件中,以延长释放和增强粘膜粘合.
- 评估开发的水凝插件对阴道真菌感染的*体外*疗效.
主要方法:
- 聚电解质复合物 (PECs) 通过溶解合成,使用素和阳离子聚合物 (卡拉基安,点,聚碳酸) 来合成.
- 使用SEM,FTIR和DSC进行PEC形成的特征; *Lactobacillus casei*的活力在溶解后被评估.
- 含有波萨可纳和PEC的水凝插件使用3^2全因子设计进行了优化,随后进行了体内*的胀,药物释放,粘结和抗真菌活性评估.
主要成果:
- 素-pectin水凝插件表现出显著的粘粘性 (1.25 N),持续的波萨可纳释放 (88.2%在8小时内),以及154.7%的胀指数.
- 在*体外*共同培养研究中,24小时内*Candida albicans*可生存数量减少了4个日志.
- 在冷化过程中, *Lactobacillus casei* 的活力保持不变,并且在抗真菌剂的存在下,其数量增加.
结论:
- 开发的奇托桑 - pectin水凝插件显示承诺作为有效的局部治疗阴道真菌感染.
- 该配方成功地结合了持续的药物释放,粘膜粘附和益生菌的输送,以恢复阴道微生物群的平衡.
- 这种先进的输送系统为管理复发性阴道感染和改善治疗结果提供了潜在的策略.
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
332
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
332
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160
01:26Oral Drug Delivery Systems: Continuous-Release Systems
308
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
308
01:11Oral Drug Delivery Systems: Delayed-Release Systems
222
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
222
01:18Transdermal Drug Delivery Systems
233
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
233
01:21Intrauterine Drug Delivery Systems
168
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
168